Lv71
3565 积分 2021-03-26 加入
Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies
27天前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
1个月前
已完结
Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen
1个月前
已完结
Population Pharmacokinetics of Mirvetuximab Soravtansine in Patients with Folate Receptor‐α Positive Ovarian Cancer: the Antibody‐Drug Conjugate, Payload and Metabolite
1个月前
已完结
Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer
1个月前
已完结
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
1个月前
已完结
Mirvetuximab soravtansine superior to chemotherapy in platinum-resistant epithelial ovarian cancer
1个月前
已完结
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
1个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
1个月前
已完结
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
2个月前
已完结
皖公网安备34019202002308
